If a Stock Market Crash Is Coming, History Shows This Stock Will Be a Brilliant Buy

The article argues Johnson & Johnson should be a recession-resistant defensive pick, noting it has historically outperformed the S&P 500 in downturns (e.g., 2008/2009 and the 2020 crash). It highlights a rock-solid balance sheet with an AAA credit rating (S&P Global) and emphasizes income appeal as a Dividend King with 64 consecutive years of dividend increases. Offsetting risks cited include patent cliffs (e.g., Stelara), ongoing U.S. drug price negotiations, and unresolved talc-related cancer lawsuits, but the author expects continued sales/earnings growth with guidance implying healthy top-line growth into 2026.

Analysis

This is less a new fundamental catalyst than a portfolio-insurance case. In a real slowdown, JNJ’s appeal is that earnings are not tightly tied to consumer impulse spending or capex cycles, so the stock should hold up better than broad indices and most cyclical healthcare names. That said, the market usually pays up for that resilience in advance, so the upside is more about relative drawdown protection than absolute alpha.

Second-order, the beneficiaries are the usual defensive bid names in XLV and other cash-rich large caps; the losers are sectors with operating leverage to consumer demand and pricing power loss, especially discretionary retail, travel, and industrials. Inside healthcare, the more vulnerable cohort is elective-procedure exposure: any recession-induced volume deferral would pressure medtech peers with high procedure sensitivity before JNJ’s diversified mix does. The flip side is that litigation and drug-pricing policy still cap multiple expansion, so the stock can be "safe" without being exciting.

The contrarian read is that recession odds may be over-discounted in defensive leadership. If inflation cools without a hard landing, JNJ risks becoming a low-growth bond proxy just as investors rotate back toward higher-duration earnings. Falsifier: a stable labor market, easing CPI, and no deterioration in guidance would likely blunt the defensive bid; a meaningful step-up in legal reserves or weaker 2026 growth guidance would invalidate the quality-premium thesis more quickly than a mild macro wobble.

Key Decisions for Investors

• Use JNJ as a macro hedge, not a core alpha long: accumulate on broad market risk-off days over the next 1-3 months, with the thesis invalidated if recession probabilities fade and defensive healthcare underperforms XLV materially.
• Pair trade: long JNJ / short XLY for a 1-3 month recession-scare hedge; this captures the spread between insulated healthcare cash flows and consumer-demand beta if macro data weaken.
• If you want cleaner defensive healthcare exposure, prefer JNJ over elective-procedure names; avoid chasing after a defensive rotation already started, since the relative upside is likely capped.
• Watch for a reversal signal in 2026 guidance and litigation headlines; if growth reaccelerates and reserves stay contained, JNJ can work as a low-volatility compounder, but if not, trim on strength.